London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Now now tiger, your the one 2nd guessing all the time, half your post have numbers in them , grow up ,
Sounds like I’m ****ed reading my post lol, should of read get some of that black gold, anyway next week or week after CF has already said it’s now a different ball game for ORPH, we will be worth more than a 100mill company and with the placing and these new investors on board I’m sure CF will take ORPH to the next level , GL
So you can second guess but I cant? Idiot.
So you think all COVID news going away do you eh lol, you get yourself back offshore and get done if that black gold, if you go back to what CF said few weeks back news every week as things moving fast , as you can tell I don’t post a lot but I read most things, I wouldn’t say I’m 2nd guessing on news next week, but if none it won’t bother me at all, but as a betting man I’d say it’s a cert , GL
News next week for sure? Maybe not. He said 7-10 days. And what COULD be a busy week? Let's not try to second guess eh?
Let’s not try and 2nd guess, news for sure next week, enjoy the weekend for what could be a busy week , GLA.
Fingers crossed we get all 12 contracts for the challenge studies starting to roll in over the coming month or so. The only other place that does them is SGS in Belgium I think? Let's hope after the media launch that all the big employing companies start rolling employees through the antibody testing. I wonder if CF could also offer support to Roche if they were overwhelmed? Anyway I'm looking forward to the coming weeks and months. GLA
Post COVID I suppose there will be demand for all sorts of other vaccines ???
Ah The Smashing Pumpkins, Tonight, Tonight. Great. GLA
I’d say you are being way to pessimistic I hope.
Now there’s good use of English
Open Orphan
Four Core Revenue Generating Businesses
1. Hvivo – Challenge study business - world leader in testing vaccines & antivirals.
2. Hvivo - Laboratory Services & Testing – e.g. Covid antibody testing (new & about to launch).
3. Venn Sciences – Drug Development.
4. Open Orphan - Genomic Health Data Platform – Pharma Company access via annual subscription.
Resulting in four prospect pipelines of revenue business expanded with Covid opportunities.
1. Existing combined pipeline of near-term target contracts for Hvivo & Venn - £110m.
2. Substantial new pipeline of opportunities to develop Covid challenges studies - £35m to £70m.
3. Third party pharma Covid laboratory testing opportunities - £5m to £10m.
4. Rollout of Covid antibody testing £10 to £30m with further potential upside.
Total Prospect Revenue Income - £160m to £220m
Non-Core for monetisation
1. Imutex – Flu -v, phase III ready universal flue vaccine + phase II ready mosiquito saliva vaccine.
2. PrEPBiopharm – Viral prophylactic with expected use against COVID-19.